United States· US:67919-040_340a4655-ccf2-4c0f-a305-7576c06f4518
SIVEXTRO
A tedizolid product containing tedizolid phosphate, registered in United States by Merck Sharp & Dohme LLC. The same ATC class is registered in 14 of our 19 countries.
Checked against FDA National Drug Code directory (United States) on
Informational only — not a medical device.
Where it is registered
Tedizolid is registered in 14 of 19 countries.
Countries holding a registration under ATC J01XX11 (tedizolid), each read from that country’s own register.
- This record: United States, from FDA National Drug Code directory (United States)
- 10 of them publish a price we can compare per daily dose
Tedizolid · ATC J01XX11
14 / 19 countries
- Belgiumprice
- Czechiaprice
- Denmark
- Finlandprice
- Franceprice
- Icelandprice
- Italyprice
- Japan
- Netherlands
- Norwayprice
- Polandprice
- Spainprice
- United Kingdom
- United Statesprice
Price per daily dose
What a daily dose of tedizolid costs, country by country.
Normalised to the WHO defined daily dose (0.2 g), so markets compare like for like.
- 1 market with a comparable price for this class
- Public list prices, converted to USD at the rate date shown
Tedizolid · price per daily dose (0.2 g)
USD · FX 28 Sept 2026
- IT Italy$346.95
The record
At a glance
FDA National Drug Code directory (United States)- Active substance
- TEDIZOLID PHOSPHATE
- Manufacturer
- Merck Sharp & Dohme LLC
- Country
- United States (US)
- ATC code
- J01XX11
- ATC class
- Tedizolid
- Defined daily dose
- 0.2 g, O
- Reimbursed
- Not published by this register
- Source register
- FDA National Drug Code directory (United States)
- Last checked
- September 27, 2026
Packs & prices · 2
- ndc1167919-040-02
- ndc11679190400210 VIAL, GLASS in 1 CARTON (67919-040-02) / 4 mL in 1 VIAL, GLASS
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Interactions
51 interactions on record for tedizolid.
Graded by severity as the source publishes them — 2 severe. Severity grades are free for everyone; mechanism and management come with Growth.
- Severity for every pair — free, no plan needed
- The source, licence and sync date on every record
- Mechanism and what to do for each pair — Growth plan
Tedizolid · interactions on record
51 records
- 2 severe
- 49 moderate
Most severe, free to view
- OzanimodL04AA38severe
- OzanimodL04AE02severe
- Sodium picosulfateA06AB08moderate
- SulfasalazineA07EC01moderate
- Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.
Same medicine, other countries
Tedizolid in 14 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
- CzechiaSIVEXTROMerck Sharp & Dohme B.V., Haarlem
- FinlandSivextroMerck Sharp & Dohme B.V.
- BelgiumSivextro 200 mgMerck Sharp & Dohme
- NetherlandsSivextro 200 mg filmomhulde tablettenMerck Sharp & Dohme B.V.
- SwedenSivextro 200 mg Filmdragerad tablettMerck Sharp & Dohme BV
- IcelandSivextroMerck Sharp & Dohme B.V.*
- SpainSIVEXTRO 200 MG COMPRIMIDOS RECUBIERTOS CON PELICULAMerck Sharp & Dohme B.V.
- United KingdomSivextro 200mg powder for concentrate for solution for infusion vialsMerck Sharp & Dohme (UK) Ltd
Authorised across Europe · EMA
The same active substance is authorised in 3 EEA countries. Names it is sold under:
- Iceland · Sivextro
- Liechtenstein · Sivextro
- Norway · Sivextro
Source: European Medicines Agency, Article 57 product data.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of FDA National Drug Code directory (United States). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/7411fc59-a1ff-4644-8f7d-22ac27d3897f GET /v1/drugs/7411fc59-a1ff-4644-8f7d-22ac27d3897f?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"route": "INTRAVENOUS",
"source": "ndc",
"strength": "200",
"substance": "TEDIZOLID PHOSPHATE",
"productndc": "67919-040",
"dosage_form": "INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION",
"dea_schedule": null,
"strength_unit": "mg/4mL",
"application_number": "NDA205436",
"marketing_category": "NDA"
}See everything about tedizolid.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.